Regulatory posture

Built for the EU AI Act.

The AI Act classifies AI for diagnosis and clinical decision support as high-risk, and mandates logging, transparency, human oversight, and demonstrable accuracy. Most tools will retrofit those. Axiisium started there.

The Act is not a threat to a product built to be verified. It is a tailwind. Every requirement it places on high-risk clinical AI, Axiisium already treats as the point of the product, not a compliance tax bolted on afterward.

Art. 12 & 19 · Record-keeping

Automatic, durable logs

High-risk systems must automatically log events and retain them for at least six months.
Axiisium binds every decision to a signed, tamper-evident record, anchored to an external append-only log. Not just retained: independently verifiable, by anyone, without trusting us.
Art. 13 · Transparency

Legible capabilities and limits

Operation must be transparent: intended purpose, accuracy level, and limitations disclosed to the deployer.
Each call shows which signal drove it, a calibrated confidence, the WHO 2022 / ICC 2022 rationale, and states plainly what is assumed and what is deferred.
Art. 14 · Human oversight

The clinician decides

Systems must let a competent human monitor operation, catch anomalies, and intervene.
A qualified clinician makes the diagnosis; a confirmatory assay gates any decision; the model ranks who to sequence but never makes the genetics call. Fail-safe by architecture, not by policy.
Art. 15 · Accuracy & robustness

Measured, not asserted

Appropriate accuracy, robustness, and cybersecurity, declared and evidenced.
Morphology assessed at a preliminary, patient-grouped, out-of-fold 0.819 to 0.977 AUROC across four AML lesions (129 AML patients, healthy donors excluded, means over 10 seeds), with one lesion reproduced on an external cohort at 0.724 and the other three not yet, calibrated confidence bands, and a configurable recall-floor that bounds the false-negative rate.
Art. 9 · Risk management

Safe by construction

A continuous risk-management process across the lifecycle.
The ranking cannot itself drive an unconfirmed clinical action: mandatory confirmatory gating and the recall-floor are properties of the pipeline, and it defers hard markers to the assay.
Art. 10 · Data governance

Provenance of the inputs

Training and evaluation data governed for quality and representativeness.
Validation is patient-grouped and leakage-free, and each signed record carries a digest of the exact inputs that produced the call.
Timeline

When it applies.

Aug 2026Core high-risk obligations apply in full: conformity assessment, technical documentation, and human oversight.
Aug 2027Extended transition for AI already regulated as a medical device under the MDR / IVDR that requires Notified Body assessment.
In fluxThe Commission's Digital Omnibus may adjust the high-risk timeline as harmonised standards mature; we track it.Update · Jun 2026The European Parliament approved Omnibus amendments shifting the deadline for AI embedded as safety components in medical devices to August 2, 2028.
⚖️ Regulatory Status & Compliance Philosophy

Axiisium is Research Use Only (RUO) today. It is not yet conformity-assessed as an in vitro diagnostic or medical device.

What we are claiming is narrow and true: the core architecture is already natively shaped around high-risk regulatory requirements. Transitioning Axiisium from RUO to a fully regulated clinical product is strictly a matter of execution, conformity assessment, and rigorous documentation, not an architectural rebuild. The auditable, human-gated, meticulously logged core is not a superficial feature we add later to pass the EU AI Act or IVDR. It is the fundamental foundation we started from.

Research Use Only. Not for diagnostic use.